People familiar with the matter said that relevant consultations are still in progress, and details such as the scale and timing of fundraising may be adjusted. A spokesperson for the SoftBank Vision Fund declined to comment, and representatives of Abogen and Mirae Asset did not immediately respond to requests for comment or were unable to comment immediately.
Abogen Biosciences announced in August that it had raised more than US$700 million in Series C financing led by Temasek Holdings and Invesco Developing Markets Fund to support the clinical development of its potential new crown vaccine and expand its product line of other vaccines and therapeutic drugs. According to a press release from Qiming Ventures, the Suzhou-based company received US$600 million in Series B financing in April.